Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL

• Status: Completed
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this clinical research study is to find out if rhIL-11（Interleukin 11） may increase the platelet count in Childhood patients with acute lymphocytic leukemia (ALL) who develop low platelet counts while receiving standard CAT（cyclophosphamide+Cytosine arabinoside+mercaptopurine，7d） therapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Children's Medical Center
• Collaborator: Xiamen Amoytop Biotech Co., Ltd.
• Treatments: Oprelvekin

Criteria

Inclusion Criteria:

• new diagnosis of ALL

• TBIL≤34umol/L，Cr≤120umol/L，a normal EF

• age <18 years

Exclusion Criteria:

• patients with uncontrolled infection

• patients with Acute congestive heart failure or chronicity cardiorespiratory functional defect or serious cardiac arrhythmias